Lacosamide Krka

Lacosamide, the active ingredient in Lacosamide Krka, is an anti‑epileptic drug presented as an oral tablet for oral use. It treats partial‑onset (focal) seizures in patients with epilepsy by stabilizing neuronal firing.

GNH USA supplies Lacosamide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU pharmacopeial standards and undergoes rigorous quality control.

Lacosamide is an anticonvulsant indicated for the management of focal seizure disorders, where it is used as an add‑on therapy.

Partial‑onset seizures: reduces seizure frequency in patients with epilepsy when added to existing therapy. Focal seizures: provides adjunctive control for patients who continue to have seizures despite monotherapy. Epilepsy (partial seizures): used as an add‑on treatment to improve overall seizure management.

The most frequently reported adverse reactions with lacosamide are generally mild to moderate in intensity.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache - Blurred vision - Diplopia

Serious or Rare Side Effects: - Cardiac conduction abnormalities such as PR‑interval prolongation - Suicidal ideation or behavior - Severe skin reactions including Stevens‑Johnson syndrome - Hypersensitivity reactions such as anaphylaxis

Lacosamide requires careful assessment of patient‑specific factors before initiation. - Renal impairment: dose may need adjustment based on renal function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: perform ECG monitoring in patients with known cardiac disease. - Pregnancy: risk unknown; use only if potential benefit justifies the risk. - Concomitant CNS depressants: may increase sedation and coordination impairment. - Store at below 25°C: keep in the original pack, protect from moisture.

Lacosamide may interact with several medicines, necessitating monitoring or avoidance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin) may reduce lacosamide plasma levels – avoid co‑administration. - Drugs that prolong PR interval (e.g., quinidine, amiodarone) may increase risk of cardiac conduction delay – avoid.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs may increase CNS depression – monitor patient for excessive sedation. - Hormonal contraceptives may have reduced efficacy – consider alternative contraception methods. - Alcohol consumption may enhance dizziness and coordination impairment – advise caution.